Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 158Keratosis, Actinic 75Lymphoma, T-Cell, Cutaneous 36Skin Neoplasms 27Mycosis Fungoides 27Lymphoma, Non-Hodgkin 25Lymphoma, Mantle-Cell 25Lymphoma, Large-Cell, Immunoblastic 25Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 25Leukemia, Lymphocytic, Chronic, B-Cell 25Hodgkin Disease 25Sezary Syndrome 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, B-Cell, Marginal Zone 24Burkitt Lymphoma 24Neoplasms 22Carcinoma, Basal Cell 22Neoplasm Metastasis 20Multiple Myeloma 20Leukemia, Myeloid, Chronic-Phase 20Leukemia, Myeloid, Accelerated Phase 20Leukemia, Hairy Cell 20Leukemia, Myeloid, Acute 19Blast Crisis 19Primary Myelofibrosis 18Lymphoma 18Uveal Melanoma 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Large-Cell, Anaplastic 17

Interventions

tebentafusp 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Nevus, Blue × Dermatologic × Clear all
NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore Ltd

Phase 3 Recruiting
540 enrolled
Dermatologic

Melanoma, Nevus, Blue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡